ERBB2 and breast carcinoma: In this study, predictive modelling of clinical and tumour specific characteristics of early-stage HER2+ breast cancer identified that age at diagnosis, ER status and level of immune cell infiltration may together be important for predicting future response to neoadjuvant therapy.